All tyrosine kinase inhibitor articles
-
NewsRoche and Nurix to advance potential best-in-class BTK degrader bexobrutideg
Collaboration agreement expands Roche’s oncology pipeline and offers therapeutic potential across immunology and neurology.
-
ArticleM&A outlook for pharma in 2025
For a strong 2025, dealmaking should be central to the life sciences strategy, says EY’s annual M&A report.